Diabetes and Possible Risks from GLP-1 Medications
Diabetes is a leading cause of sight impairment in individuals aged 18 to 64, as stated by the American Diabetes Association. Managing blood sugar effectively is crucial to preventing this issue.
Glucagon-like peptide-1 receptor agonists (GLP-1), such as Ozempic and Munjaro, are becoming standard treatments for diabetes and obesity. However, recent research from Canada indicates that these medications could have unexpected side effects, especially related to eye health.
Impact of GLP-1 Medications
A study analyzing data from January 2020 to November 2023 reviewed over 139,000 diabetic patients. Some had been using GLP-1 medications for a minimum of six months, while others had gone without any diabetes drugs for three years. The participants’ average age was about 66 years, with nearly half being female.
The research revealed that those on weight-loss drugs had a twofold increase in the likelihood of developing neovascular age-related macular degeneration (NAMD) compared to those who weren’t using these medications.
“We’re receiving more reports on this,” explained a professor of ophthalmology at the University of Toronto. “Although eye issues are potential side effects of GLP-1 medications, it’s unclear how they affect the progression of age-related macular degeneration (AMD).”
What Is Age-Related Macular Degeneration?
According to the American Association of Retinal Professionals, AMD is the most prevalent cause of vision loss in people over 50, affecting around 20 million adults in the U.S. It primarily impacts central vision, meaning it can become difficult for individuals to see straight ahead, although their peripheral vision remains intact.
There are two types of AMD: dry and wet. The more common dry AMD happens when yellow protein deposits build up under the retina. Symptoms often go unnoticed in the early stages. In about 20% of cases, dry AMD can progress to the wet type, which can cause severe vision loss due to leaking blood vessels beneath the retina.
“With wet AMD, patients may experience a loss of central vision, distortions, or dark spots in their vision,” said an ophthalmology assistant professor from the University of Utah. Chronic conditions like heart failure and kidney disease, which are also frequently observed in people taking GLP-1 medications, heighten the risk for NAMD.
Study Limitations and Advice
The study’s authors urged caution in interpreting the findings, considering the already high incidence of eye disease among older adults. In the general population, about 1 in 1,000 individuals develop NAMD, but among GLP-1 users, this risk rises to 1 in 500. Yet it’s worth noting that the absolute risk remains relatively low.
This observational study cannot definitively establish a causal link between GLP-1 medications and neovascular age-related macular degeneration, as recognized by the researchers. They also pointed out that the findings pertain mostly to diabetic patients over 66, and implications for younger populations remain uncertain.
“While the likelihood of developing macular degeneration with GLP-1 use is low, there’s a need for patients to be aware of potential eye-related side effects,” one researcher emphasized.
Experts recommend monitoring for symptoms such as blurred vision or new blind spots and advising immediate medical attention if such issues arise. Early detection is critical for preventing vision loss, and the researchers hope their work encourages vigilance among patients regarding eye health.
